The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS

Last updated: December 11, 2023
Sponsor: Simcere Pharmaceutical Co., Ltd
Overall Status: Active - Not Recruiting

Phase

3

Condition

Thrombosis

Blood Clots

Stroke

Treatment

Placebo

Edaravone Dexborneol Sequential Therapy

Clinical Study ID

NCT06176781
SIM0308-302
  • Ages 18-80
  • All Genders

Study Summary

SIM0308-302 is a multicenter, randomized, double-blind, placebo-controlled clinical III trial with the primary objective of evaluating the efficacy of Edaravone Dexborneol sequential therapy, consisting of Edaravone Dexborneol Injections followed by Edaravone Dexborneol Sublingual Tablets for total 14 days, in patients with acute ischemic stroke (AIS). The subject has a clinical diagnosis of AIS, within 48 hours from stroke onset to start of study treatment, with a National Institutes of Health Stroke Scale (NIHSS) between 6 and 20, had a total score of upper and lower limbs on motor deficits ≥ 2. The primary outcome is the proportion of subjects with modified Rankin scale score ≤ 2 at 90 days after treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

    1. Aged from 18 to 80 years old, male or female; 2. Baseline National Institutes ofHealth Stroke Scale (NIHSS) score between 6 and 20, a sum scores of the fifth upperlimb and the sixth lower limb ≥2 at admission; 3. AIS symptom onset within 48 hours,onset time defined as when the patient was last known to be well; 4. According to the "Diagnostic criteria of cerebrovascular diseases in China (version 2019)", patientswere diagnosed with ischemic stroke, with their first onset or recovered well afterthe last onset (mRS score ≤ 1 point before this onset); 5. Informed consent from thepatient or legally authorized representative.

Exclusion

Exclusion Criteria:

    1. Intracranial bleeding disorders which were confirmed by cranial computed tomographyscan, including hemorrhagic stroke, epidural hematoma, intracranial hematoma,intraventricular hemorrhage, subarachnoid hemorrhage, etc; 2. Severe disturbance ofconsciousness: NIHSS category 1a for consciousness >1; 3. Transient ischemic attack (TIA); 4. Systolic blood pressure ≥ 220 mmHg or diastolic blood pressure ≥ 120 mmHgafter blood pressure control; 5. Severe mental disorder and dementia; 6. Alanineaminotransferase or aspartate transaminase > 2.0 × upper limit of normal value (ULN)or with known liver disorder, such as acute hepatitis, chronic active hepatitis,hepatic cirrhosis, etc； 7. Known kidney disease, renal insufficiency, serum creatinine > 1.5 × ULN or creatinine clearance < 50mL/min； 8. Received neuroprotective agentsafter this onset, including commercially available edaravone, edaravone dexborneolinjection，nimodipine, ganglioside, citicoline, piracetam, butylphthalide, urinarykallidinogenase, etc； 9. Received or planed Embolectomy or interventional therapyafter this onset； 10. Concurrent malignant tumor or currently receive antitumortreatment； 11. Severe systemic disease and life expectancy < 90 days; 12. Allergies toedaravone, dexborneol, or the excipients; 13. Pregnant or lactating patients orpatients who plan to become pregnant; 14. History of a major surgery within 4 weeksbefore enrollment; 15. Participated in other clinical trials within 30 days beforerandomization or currently involved in other clinical trials; 16. Investigatorsconsider they are not suitable for this trial.

Study Design

Total Participants: 880
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
December 28, 2023
Estimated Completion Date:
May 30, 2025

Study Description

SIM0308-302 is a multicenter, randomized, double-blind, placebo-controlled clinical III trial with the primary objective of evaluating the efficacy of Edaravone Dexborneol sequential therapy, consisting of Edaravone Dexborneol Injections followed by Edaravone Dexborneol Sublingual Tablets for total 14 days, in patients with acute ischemic stroke (AIS). The subject has a clinical diagnosis of AIS, within 48 hours from stroke onset to start of study treatment, with a NIHSS score between 6 and 20, had a total score of upper and lower limbs on motor deficits ≥ 2. The primary outcome is the proportion of subjects with modified Rankin scale score ≤ 1 at 90 days after treatment. The secondary outcomes included mRS score on day 90, the proportion of subjects with mRS score ≤2 on day 90, the change of NIHSS score from baseline to day 14 and the proportion of subjects with NIHSS score ≤1 on day 14, 30, 90 after treatment. Safety outcomes included adverse events, treatment related adverse events within day 90, and changes in vital signs and laboratory data before and after treatment.

Subjects in the Sequential group receive Edaravone Dexborneol concentrated solution for injections 37.5 mg BID administered intravenously for 5 - 10 days, and then followed by Edaravone Dexborneol Sublingual Tablets 30 mg BID administered sublingually for the last days, the total duration of treatment was 14 days. Subjects in the Placebo group receive placebo for 14 days. All the subjects were followed up to day 90 after the treatment.